Operational efficiencies of using one vs multiple bispecific antibodies for diffuse large B-cell lymphoma and...

To quantify the time- and cost-savings to US oncology practices from using a single bispecific antibody (bsAb) for both relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) compared with using two separate single-indication therapies.

The study conducted a national survey of clinicians (oncologists, pharmacists, nurses/physician assistants) treating non-Hodgkin lymphoma (NHL) patients in the US to quantify the impact of operational efficiencies identified through formative qualitative interviews with oncology staff. Quantitative analysis estimated time-savings based on survey data, assuming one new prescription per patient per year and 12 (DLBCL) and 15 (FL) administration visits per patient per year. Time-savings were combined with staff wage rates to estimate cost-savings.

Among n = 105 respondents, drivers of operational efficiencies included onboarding, coordinating insurance and financial aid, and medication preparation. For a hypothetical community practice treating 100 bsAb-eligible patients (61% DLBCL, 39% FL), total time-savings were 3110 h in the first year of adoption, resulting in total monetized time-savings of $278,013. For a hypothetical academic practice, monetized time-savings were $963,074 in the first year of adoption.

Using a single bsAb to treat R/R DLBCL and FL is predicted to lead to considerable time- and cost-savings for oncology practices.